• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Bruton's tyrosine kinase inhibitor associated localized extremity edema and erythema.

作者信息

Meledathu Shannon, Chu Paul, Feldman Tatyana, Goy Andre Henri, Rosenstein Rachel Kushner

机构信息

Hackensack Meridian School of Medicine, Nutley, New Jersey.

Bridge Dermpath, Tarrytown, New York.

出版信息

JAAD Case Rep. 2024 Oct 16;54:93-97. doi: 10.1016/j.jdcr.2024.10.001. eCollection 2024 Dec.

DOI:10.1016/j.jdcr.2024.10.001
PMID:39687072
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11648188/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fe6/11648188/a14129e14827/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fe6/11648188/91b8e858504a/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fe6/11648188/560d7a8ac294/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fe6/11648188/a14129e14827/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fe6/11648188/91b8e858504a/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fe6/11648188/560d7a8ac294/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fe6/11648188/a14129e14827/gr3.jpg

相似文献

1
Bruton's tyrosine kinase inhibitor associated localized extremity edema and erythema.布鲁顿酪氨酸激酶抑制剂相关的局限性肢体水肿和红斑。
JAAD Case Rep. 2024 Oct 16;54:93-97. doi: 10.1016/j.jdcr.2024.10.001. eCollection 2024 Dec.
2
ASK120067 potently suppresses B-cell or T-cell malignancies and by inhibiting BTK and ITK.ASK120067通过抑制布鲁顿酪氨酸激酶（BTK）和白细胞介素-2诱导的T细胞激酶（ITK），有效抑制B细胞或T细胞恶性肿瘤。
Front Pharmacol. 2022 Dec 15;13:1071114. doi: 10.3389/fphar.2022.1071114. eCollection 2022.
3
Effect of Bruton's tyrosine kinase inhibitors on platelet aggregation in patients with acute myocardial infarction.布鲁顿酪氨酸激酶抑制剂对急性心肌梗死患者血小板聚集的影响。
Thromb Res. 2019 Jul;179:64-68. doi: 10.1016/j.thromres.2019.04.024. Epub 2019 Apr 24.
4
Localized upper extremity edema secondary to Bruton's tyrosine kinase inhibition.布鲁顿酪氨酸激酶抑制继发的局限性上肢水肿
Leuk Lymphoma. 2023 Dec;64(12):2047-2050. doi: 10.1080/10428194.2023.2245091. Epub 2023 Sep 6.
5
Long-term follow-up and future direction on the management of chronic lymphocytic leukemia/small lymphocytic leukemia.慢性淋巴细胞白血病/小淋巴细胞白血病管理的长期随访和未来方向。
J Oncol Pharm Pract. 2022 Dec;28(8):1869-1884. doi: 10.1177/10781552221103820. Epub 2022 May 30.
6
Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model.布鲁顿酪氨酸激酶抑制剂在霍奇金淋巴瘤细胞和皮下肿瘤模型中的临床前抗肿瘤活性
Heliyon. 2019 Aug 31;5(8):e02290. doi: 10.1016/j.heliyon.2019.e02290. eCollection 2019 Aug.
7
Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib.布鲁顿酪氨酸激酶抑制剂及其在治疗 B 细胞恶性肿瘤中的临床潜力：以伊布替尼为例。
Ther Adv Hematol. 2014 Aug;5(4):121-33. doi: 10.1177/2040620714539906.
8
Novel Bruton's tyrosine kinase inhibitor TAS5315 suppresses the progression of inflammation and joint destruction in rodent collagen-induced arthritis.新型布鲁顿酪氨酸激酶抑制剂 TAS5315 抑制啮齿动物胶原诱导性关节炎的炎症进展和关节破坏。
PLoS One. 2023 Feb 23;18(2):e0282117. doi: 10.1371/journal.pone.0282117. eCollection 2023.
9
The promising impact of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the management of lymphoid malignancies.布鲁顿酪氨酸激酶抑制剂依鲁替尼在治疗淋巴系统恶性肿瘤方面具有显著疗效。
Pharmacotherapy. 2014 Mar;34(3):303-14. doi: 10.1002/phar.1366. Epub 2013 Dec 12.
10
Correction: Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.更正：慢性淋巴细胞白血病和淋巴瘤中的布鲁顿酪氨酸激酶抑制剂
Clin Adv Hematol Oncol. 2016 Sep;14(9):728.

本文引用的文献

1
Localized upper extremity edema secondary to Bruton's tyrosine kinase inhibition.布鲁顿酪氨酸激酶抑制继发的局限性上肢水肿
Leuk Lymphoma. 2023 Dec;64(12):2047-2050. doi: 10.1080/10428194.2023.2245091. Epub 2023 Sep 6.
2
Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects.BTK抑制剂的比较分析及不良反应的潜在机制
Front Cell Dev Biol. 2021 Mar 11;9:630942. doi: 10.3389/fcell.2021.630942. eCollection 2021.
3
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
一项随机 3 期临床试验，比较 zanubrutinib 与 ibrutinib 在有症状的华氏巨球蛋白血症中的疗效：ASPEN 研究。
Blood. 2020 Oct 29;136(18):2038-2050. doi: 10.1182/blood.2020006844.
4
Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.布鲁顿酪氨酸激酶抑制剂的皮肤毒性。
Am J Clin Dermatol. 2020 Dec;21(6):799-812. doi: 10.1007/s40257-020-00535-x.
5
Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor-induced dermatologic adverse events.伊布替尼引起的酷似表皮生长因子受体抑制剂所致皮肤不良反应的皮肤疹。
J Am Acad Dermatol. 2023 Jun;88(6):1271-1281. doi: 10.1016/j.jaad.2019.12.031. Epub 2019 Dec 20.
6
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.3 项关键性研究中单药伊布替尼治疗慢性淋巴细胞白血病患者的长期安全性。
Blood Adv. 2019 Jun 25;3(12):1799-1807. doi: 10.1182/bloodadvances.2018028761.
7
Incidence of peripheral edema in patients receiving PI3K/mTOR/CDK4/6 inhibitors for metastatic breast cancer.转移性乳腺癌患者接受 PI3K/mTOR/CDK4/6 抑制剂治疗后的外周水肿发生率。
Breast Cancer Res Treat. 2019 Jun;175(3):649-658. doi: 10.1007/s10549-019-05206-y. Epub 2019 Mar 27.
8
Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.依鲁替尼增加心房颤动风险，可能是通过抑制心脏PI3K-Akt信号传导实现的。
Blood. 2014 Dec 11;124(25):3829-30. doi: 10.1182/blood-2014-10-604272.
9
Rituximab: rescue therapy in life-threatening complications or refractory autoimmune diseases: a single center experience.利妥昔单抗：挽救危及生命的并发症或难治性自身免疫性疾病的治疗方法：单中心经验。
Rheumatol Int. 2013 Jun;33(6):1495-504. doi: 10.1007/s00296-012-2587-x. Epub 2012 Dec 14.
10
Systemic adverse events following rituximab therapy in patients with Graves' disease.利妥昔单抗治疗格雷夫斯病患者的系统性不良反应。
J Endocrinol Invest. 2011 Jul-Aug;34(7):e163-7. doi: 10.3275/7411. Epub 2010 Dec 15.